From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle

Pharma companies have spent the last several years testing AI across discovery, development, manufacturing, and commercialization. With the potential to create $60 billion to $110 billion annual economic value across the industry, AI has become too important to remain stuck in pilot mode. Today, only a small group of companies is starting to turn AI into measurable business gains, with Boston Consulting Group finding that AI-first biopharma companies are reporting 5 percent to 15 percent revenue uplift.